Blue Jet Healthcare Limited has filed its quarterly compliance certificate with the stock exchanges for the quarter ended March 31, 2026. The pharmaceutical company submitted the mandatory documentation to both BSE Limited and the National Stock Exchange of India Limited on April 08, 2026.

Regulatory Compliance Details

The compliance certificate was issued under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. MUFG Intime India Private Limited, formerly known as Link Intime India Pvt. Ltd., serves as the company's Registrar and Share Transfer Agent and issued the certificate on April 02, 2026.

Share Holding Status

The certificate confirms that Regulation 74(5) is not applicable to Blue Jet Healthcare Limited, as the entire holding of the company's shares remains in demat form. MUFG Intime India Private Limited reported that no requests were received from any members of the company for rematerialisation during the quarter ended March 31, 2026.

Corporate Information

Blue Jet Healthcare Limited operates from its registered and corporate office located at 701 & 702, Bhumiraj Costarica, Plot 1 & 2, Sector - 18, Sanpada, Navi Mumbai - 400705. The company maintains three manufacturing units across Maharashtra, including facilities in Shahad, Ambernath, and Mahad.

Filing Authority

The compliance certificate was signed by Sweta Poddar, Company Secretary and Compliance Officer (Membership No.: F12287), on behalf of Blue Jet Healthcare Limited. The digital signature was applied on April 08, 2026, at 11:41:41 +05'30'.

This quarterly filing represents part of the company's ongoing regulatory compliance obligations with the Securities and Exchange Board of India and demonstrates the complete digitisation of its shareholding structure.

Blue Jet Healthcare Limited held the groundbreaking ceremony for its new manufacturing facility at Industrial Park Rambilli Cluster Phase II, Anakapalli District, Andhra Pradesh on February 28, 2026. The ceremony was attended by Hon'ble Minister for IT, Electronics & Communications and HRD, Shri Nara Lokesh, along with senior officials of the Government of Andhra Pradesh, industry partners, customers, and investors.

Board-Approved Investment and Development Plans

The company's Board of Directors has approved Phase 1 of the project with a substantial investment commitment. The facility represents a strategic expansion initiative with significant long-term development potential.

Manufacturing Focus and Capabilities

The Vizag facility will concentrate on producing complex pharmaceutical intermediates and active pharmaceutical ingredients (APIs). This strategic focus aims to strengthen Blue Jet Healthcare's capabilities as a global supplier to pharmaceutical innovators. The project is designed to enhance the company's manufacturing platform to meet evolving pharmaceutical supply-chain requirements.

At full scale, the project is expected to generate high-skilled direct employment opportunities and contribute significantly to the development of the regional industrial ecosystem.

Management Commentary

Mr. Shiven Arora, Managing Director, emphasized the milestone's importance in the company's expansion strategy: "Phase 1 marks an important milestone in our long-term expansion strategy. We appreciate the clarity and responsiveness extended by the Government of Andhra Pradesh, which provided the confidence to invest at scale. Our objective is to develop a globally benchmarked manufacturing platform aligned with evolving pharmaceutical supply-chain requirements."

Mr. Akshay Arora, Executive Chairman, highlighted the company's growth trajectory: "Founded in 1968, Blue Jet Healthcare has grown with a strong focus on governance and long-term partnerships. The Vizag project represents a disciplined expansion aligned with global demand and the Company's multi-decade growth plans."

Strategic Alignment

The project aligns with Andhra Pradesh's industrial development objectives and supports India's broader agenda of strengthening advanced manufacturing and supply-chain resilience. Blue Jet Healthcare, established in 1968, operates as a manufacturer of specialty chemicals and pharmaceutical intermediates serving global pharmaceutical companies, maintaining focus on quality, compliance, and governance-led growth.